Hoteles City Express. de Valuation
Is HCITY * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HCITY * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HCITY * (MX$4.58) is trading below our estimate of fair value (MX$26.27)
Significantly Below Fair Value: HCITY * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HCITY *?
Other financial metrics that can be useful for relative valuation.
What is HCITY *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | Mex$1.89b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.9x |
Enterprise Value/EBITDA | 6.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does HCITY *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.4x | ||
CIDMEGA * Grupe. de | 0.7x | n/a | Mex$2.3b |
HOTEL * Grupo Hotelero Santa Fe. de | 0.9x | 8.1% | Mex$2.6b |
POSADAS A Grupo Posadas. de | 1.6x | n/a | Mex$14.3b |
RLH A RLH Properties. de | 2.6x | n/a | Mex$19.2b |
HCITY * Hoteles City Express. de | 0.5x | 5.5% | Mex$1.9b |
Price-To-Sales vs Peers: HCITY * is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (1.4x).
Price to Earnings Ratio vs Industry
How does HCITY *'s PE Ratio compare vs other companies in the South American Hospitality Industry?
Price-To-Sales vs Industry: HCITY * is good value based on its Price-To-Sales Ratio (0.5x) compared to the South American Hospitality industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is HCITY *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.5x |
Fair PS Ratio | 0.4x |
Price-To-Sales vs Fair Ratio: HCITY * is expensive based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$4.58 | Mex$8.25 +80.1% | 33.3% | Mex$11.00 | Mex$5.50 | n/a | 2 |
Apr ’25 | Mex$5.09 | Mex$8.50 +67.0% | 29.4% | Mex$11.00 | Mex$6.00 | n/a | 2 |
Mar ’25 | Mex$4.95 | Mex$8.50 +71.7% | 29.4% | Mex$11.00 | Mex$6.00 | n/a | 2 |
Feb ’25 | Mex$5.46 | Mex$8.50 +55.7% | 29.4% | Mex$11.00 | Mex$6.00 | n/a | 2 |
Dec ’24 | Mex$5.55 | Mex$10.00 +80.2% | 10.0% | Mex$11.00 | Mex$9.00 | n/a | 2 |
Nov ’24 | Mex$5.62 | Mex$10.00 +77.9% | 10.0% | Mex$11.00 | Mex$9.00 | n/a | 2 |
Oct ’24 | Mex$6.81 | Mex$10.00 +46.8% | 10.0% | Mex$11.00 | Mex$9.00 | n/a | 2 |
Sep ’24 | Mex$6.93 | Mex$10.00 +44.3% | 10.0% | Mex$11.00 | Mex$9.00 | n/a | 2 |
Aug ’24 | Mex$6.84 | Mex$10.00 +46.2% | 10.0% | Mex$11.00 | Mex$9.00 | n/a | 2 |
Jul ’24 | Mex$7.17 | Mex$9.50 +32.5% | 5.3% | Mex$10.00 | Mex$9.00 | n/a | 2 |
Jun ’24 | Mex$7.99 | Mex$9.50 +18.9% | 5.3% | Mex$10.00 | Mex$9.00 | n/a | 2 |
May ’24 | Mex$8.29 | Mex$9.50 +14.6% | 5.3% | Mex$10.00 | Mex$9.00 | n/a | 2 |
Apr ’24 | Mex$8.50 | Mex$9.50 +11.8% | 5.3% | Mex$10.00 | Mex$9.00 | Mex$5.09 | 2 |
Mar ’24 | Mex$8.33 | Mex$9.50 +14.0% | 5.3% | Mex$10.00 | Mex$9.00 | Mex$4.95 | 2 |
Feb ’24 | Mex$7.75 | Mex$7.50 -3.2% | 33.3% | Mex$10.00 | Mex$5.00 | Mex$5.46 | 2 |
Jan ’24 | Mex$8.43 | Mex$7.50 -11.0% | 33.3% | Mex$10.00 | Mex$5.00 | Mex$5.93 | 2 |
Dec ’23 | Mex$6.66 | Mex$7.50 +12.6% | 33.3% | Mex$10.00 | Mex$5.00 | Mex$5.55 | 2 |
Nov ’23 | Mex$5.38 | Mex$7.50 +39.4% | 33.3% | Mex$10.00 | Mex$5.00 | Mex$5.62 | 2 |
Oct ’23 | Mex$3.57 | Mex$8.50 +138.1% | 17.6% | Mex$10.00 | Mex$7.00 | Mex$6.81 | 2 |
Sep ’23 | Mex$3.71 | Mex$8.50 +129.1% | 17.6% | Mex$10.00 | Mex$7.00 | Mex$6.93 | 2 |
Aug ’23 | Mex$3.84 | Mex$8.50 +121.4% | 17.6% | Mex$10.00 | Mex$7.00 | Mex$6.84 | 2 |
Jul ’23 | Mex$3.95 | Mex$8.50 +115.2% | 17.6% | Mex$10.00 | Mex$7.00 | Mex$7.17 | 2 |
Jun ’23 | Mex$4.06 | Mex$8.50 +109.4% | 17.6% | Mex$10.00 | Mex$7.00 | Mex$7.99 | 2 |
May ’23 | Mex$4.99 | Mex$8.50 +70.3% | 17.6% | Mex$10.00 | Mex$7.00 | Mex$8.29 | 2 |
Apr ’23 | Mex$5.26 | Mex$9.75 +85.4% | 2.6% | Mex$10.00 | Mex$9.50 | Mex$8.50 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.